Xenon Pharmaceuticals Inc.
XENE
$58.78
-$0.78-1.30%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -30.73% | -57.27% | -60.25% | -44.76% | -46.24% |
| Total Depreciation and Amortization | -11.71% | -10.93% | -8.26% | -3.90% | -1.40% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -28.23% | 8.49% | 88.24% | -1.04% | 5.41% |
| Change in Net Operating Assets | -7.32% | 72.28% | 190.23% | 505.47% | -73.22% |
| Cash from Operations | -48.51% | -44.19% | -49.82% | -44.47% | -106.19% |
| Capital Expenditure | -75.16% | -209.30% | 59.39% | 52.37% | 89.63% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -501.57% | -1,278.33% | -36.53% | 3,467.28% | -25.55% |
| Cash from Investing | -502.67% | -1,280.19% | -36.35% | 7,637.15% | -24.66% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -60.00% | 73,141.79% | 836.00% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -60.00% | 73,141.79% | 836.00% | -- | -- |
| Foreign Exchange rate Adjustments | -58.54% | -103.13% | 91.01% | -111.11% | 412.87% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -2,376.97% | 1,430.66% | 71.80% | 37.15% | -75.94% |